Target intelligence / Profile preview

Occludin (OCLN)

Target
OCLN
Molecular classification
Integral membrane protein, Tight junction protein, Other (sometimes classified as a co-receptor for certain viruses)
01

Overview

Occludin is an integral membrane protein (~65 kDa) localized primarily at the tight junctions between epithelial and endothelial cells. It plays a central role in regulating paracellular permeability by forming part of the physical seal between adjacent cells. Occludin has four transmembrane domains with two extracellular loops critical for cell-cell adhesion. Its cytoplasmic C-terminal domain interacts with scaffolding proteins like ZO‑1/ZO‑2/ZO‑3 and F-actin to anchor it within the cellular architecture. Beyond its structural role at tight junctions, recent evidence suggests that occludin also participates in cell signaling pathways affecting metabolism and gene expression. Disruption or downregulation of occludin contributes to various pathologies involving compromised tissue barriers—including neurological disorders linked to genetic mutations in OCLN—and serves as an essential co-receptor facilitating hepatitis C virus entry into hepatocytes. Multiple isoforms exist due to alternative splicing; post-translational modifications such as phosphorylation regulate its localization/functionality within tissues.

Other names
OCLNTight junction protein occludin
02

Mechanism of action

For experimental drugs/agents targeting occludin or its pathway: - Modulation of tight junction integrity/permeability - Inhibition of viral entry by blocking co-receptor function for HCV

03

Biological functions

Regulation of tight junction permeability barrierCell-cell adhesion at tight junctionsParacellular transport regulationCo-receptor activity for hepatitis C virus (HCV) entry into hepatocytesCell signaling, including influence on glucose uptake, ATP production, gene expression, and interaction with transcription factors such as NFkB and sirtuins
04

Disease associations

Neurological disorders (e.g., band-like calcification with simple gyration and polymicrogyria/BLC-PMG)Barrier dysfunction in inflammation or infection (e.g., gut or blood-brain barrier disruption)Viral infection (notably hepatitis C virus entry)Potential roles in cancer progression due to altered cell adhesion/barrier function
05

Safety considerations

Potential safety concerns include disruption of essential tissue barriers leading to increased paracellular permeability—risking edema, inflammation, infection spread across barriers such as the gut epithelium or blood-brain barrier if targeted therapeutically.
06

Interacting drugs

No approved drugs directly target occludin clinically. However, experimental agents that modulate tight junctions or block HCV entry may interact with occludin. Specific drug names are not established in clinical use as of now.
07

Biomarkers

Altered expression/localization/phosphorylation state of occludin can serve as a biomarker for epithelial/endothelial barrier integrity in research settings; not widely used clinically yet but under investigation for disease monitoring where barrier function is relevant

Beyond the preview

Go deeper on Occludin (OCLN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Occludin (OCLN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call